What is the Small‑Fiber Neuropathy Screening List (SFNSL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is the Small Fiber Neuropathy Screening List (SFNSL)?

The Small Fiber Neuropathy Screening List (SFNSL) is a validated 21-item questionnaire designed to screen for small fiber neuropathy in clinical practice, with a score ≥11 indicating a positive screen for SFN. 1

Development and Validation

The SFNSL was originally constructed and cross-validated in a sarcoidosis population of 139 patients 1. The development process involved:

  • Initial cohort (n=84): Patients underwent temperature threshold testing (TTT) and completed an extensive SFN-symptoms questionnaire
  • Statistical methodology: Distribution measures and discriminant analyses were used to distill the questionnaire down to 21 key questions
  • Cross-validation cohort (n=55): The same cut-off scores proved appropriate in this independent group

Psychometric Properties

The SFNSL demonstrates strong measurement characteristics:

  • Internal consistency: Cronbach's alpha of 0.90, indicating excellent reliability 1
  • Factor structure: Measures only one underlying factor (unidimensional) 1
  • Convergent validity: Good correlation with objective measures of small fiber function 1

Diagnostic Performance

The SFNSL shows high diagnostic accuracy when validated against objective testing:

In a Chinese validation study of 55 patients, the SFNSL demonstrated 2:

  • Sensitivity: 94.1%
  • Specificity: 90.9%
  • Optimal cut-off score: ≥8 (in this population)
  • Correlation with intraepidermal nerve fiber density (IENFD): High correlation, superior to other screening tools

The original sarcoidosis study used a cut-off of ≥11 1, while the Chinese study found ≥8 optimal 2, suggesting potential population-specific variations that clinicians should consider.

Clinical Applications

The SFNSL has been successfully applied across multiple disease populations:

  • Sarcoidosis: 50% of Pompe disease patients screened positive (mean score 11.6) 3
  • Pompe disease: Detected SFN in 77.8% of patients without neuropathy complaints 4
  • General SFN screening: Correlates with disease severity and improves diagnostic performance when combined with thermal threshold testing 5

Practical Use in Clinical Settings

The SFNSL serves as a brief, easy-to-administer screening tool that:

  • Assesses both frequency and severity of SFN symptoms 6
  • Can identify patients who warrant further diagnostic workup (skin biopsy, quantitative sensory testing)
  • Correlates with continuous length-dependent pain patterns specifically 7
  • Shows modest correlation with age (r=0.38) and duration of enzyme replacement therapy in Pompe disease (r=0.31) 3

Important Clinical Caveats

Gender differences: Women demonstrate significantly higher mean SFNSL scores (14.2) compared to men (8.2, p=0.017) in Pompe disease populations 3, suggesting potential need for sex-specific interpretation.

Phenotype specificity: The SFNSL correlates most strongly with continuous length-dependent symptoms (R=0.3, p=0.03) 7. Patients with intermittent or non-length-dependent presentations may require additional diagnostic methods beyond thermal threshold testing, as TTT shows correlation only with the continuous length-dependent phenotype 7.

Diagnostic enhancement: Combining the SFNSL with thermal threshold testing improves overall diagnostic performance 5, making it a valuable adjunct rather than standalone diagnostic tool.

Role in Diagnostic Algorithm

The SFNSL functions as a first-line screening instrument that can:

  • Identify patients requiring confirmatory testing (skin biopsy remains the gold standard) 8
  • Quantify symptom burden for monitoring disease progression
  • Facilitate early detection in at-risk populations (diabetes, autoimmune diseases, sarcoidosis)

References

2
Research

SFN-SIQ, SFNSL and skin biopsy of 55 cases with small fibre involvement.

The International journal of neuroscience, 2018

6
Research

Small Fiber Neuropathy in Sarcoidosis.

Seminars in respiratory and critical care medicine, 2025

Related Questions

What does a non‑length‑dependent pattern refer to in small‑fiber neuropathy?
Can an acute bacterial infection (e.g., cellulitis, urinary tract infection, or respiratory infection) exacerbate the pain, burning, tingling, or autonomic symptoms in an adult patient with known small‑fiber neuropathy?
In a 25‑year‑old man with severe orthostatic hypotension and small‑fiber neuropathy who is taking phenelzine (irreversible monoamine oxidase inhibitor) and chronic lithium therapy, what is the most likely cause of his condition and what are the recommended next steps in management?
Which autoantibody tests are recommended for evaluating suspected immune‑mediated small‑fiber neuropathy?
Which psychiatric medications should be avoided in patients with dysautonomia?
Is it appropriate for a patient with congestive heart failure and volume overload to be treated with bumetanide (Bumex) 2 mg twice daily, acetazolamide, and metolazone?
What is the recommended management for Modic type 1 degenerative endplate changes causing low back pain?
How can I switch from Abilify Maintena (aripiprazole) long‑acting injectable to oral aripiprazole?
What premedication regimen should be used prior to carfilzomib infusion?
What does a hematocrit of 39% and hemoglobin of 13.0 g/dL indicate in a 64‑year‑old male, and what are the recommended next steps?
Can military service worsen the symptoms of pes planus (flatfoot)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.